SoundHound AI and Allina Health Launch AI Agent to Redefine Patient Engagement
Average call time has improved by 5–10 seconds, and 80% of calls are now answered in 45 seconds or less, without increasing staffing levels.
Share
Alli answers calls within Allina Health's Customer Experience Center and integrates directly with Allina Health's electronic medical record system, allowing it to instantly identify and authenticate callers. The AI agent allows patients to manage their appointments, and in the future patients will be able to refill medications, find doctors or locations, and receive answers to non-clinical questions – all without having to wait on hold. This eliminates the need for customer experience representatives to spend time on manual verification, accelerating access to care.
Since launch, Alli has significantly improved operational performance for Allina Health. Average call time has improved by 5–10 seconds, and 80% of calls are now answered in 45 seconds or less, without increasing staffing levels.
'One of our key goals is to make sure that we're providing a market-leading patient experience,' said David Ingham, DO, Allina Health Chief Information Officer. 'Alli is an extension of our team, and we're excited to have her on board to streamline operations, reduce wait times, and deliver a faster, more seamless experience for our patients.'
By offloading routine tasks to Alli, Allina Health's customer experience representatives are now able to focus on patients who have more complex or sensitive needs, providing the white-glove service and personalized support those situations require. Patients also benefit from increased self-service capabilities, gaining more control over their care journey through fast, convenient access to answers and actions.
'Long wait times and administrative complexity can be a huge source of stress for patients,' said Michael Anderson, Executive Vice President of Enterprise AI at SoundHound AI. 'We are proud to partner with Allina Health on this important digital transformation. The organization is taking a forward-thinking approach by integrating AI to support patients with immediate, personalized assistance.'
SoundHound provides healthcare organizations with AI agents that leverage the latest in conversational and generative AI technology, ensuring reliability, security, and scalability. These AI agents are HIPAA-compliant and available across any voice- or chat-based channel to answer patient questions and automate self-service tasks through natural-language conversations.
For more information on SoundHound's Amelia AI Agents for Healthcare, visit: https://www.soundhound.com/voice-ai-solutions/healthcare/
For more information on SoundHound AI, visit: https://www.soundhound.com/
About SoundHound AI
SoundHound AI (Nasdaq: SOUN), a global leader in voice and conversational intelligence, delivers AI solutions that allow businesses to offer superior experiences to their customers. Built on proprietary technology, SoundHound's voice AI delivers best-in-class speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants. The company's various groundbreaking AI-driven products include Smart Answering, Smart Ordering, Dynamic Drive-Thru, and the Amelia Platform, which powers AI Agents for enterprise. In addition, SoundHound Chat AI, a powerful voice assistant with integrated Generative AI, and Autonomics, a category-leading operations platform that automates IT processes, have allowed SoundHound to power millions of products and services, and processes billions of interactions each year for world class businesses.
About Allina Health
Allina Health is dedicated to the prevention and treatment of illness and enhancing the greater health of individuals, families and communities throughout Minnesota and western Wisconsin. A nonprofit health care system, Allina Health cares for patients from beginning to end-of-life through its 90+ clinics, 12 hospital campuses, 13 retail pharmacies, and many specialty care centers and specialty medical services, home care, and emergency medical transportation services. Learn more at allinahealth.org and join us on Facebook, X, Instagram and LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Orion Energy announces 1-for-10 reverse stock split
Orion Energy (OESX) announced that its board of directors and shareholders approved a 1-for-10 reverse stock split of the company's common stock, no par value per share, which will be effective at 12:01 a.m., Central Time, on August 22. Orion's common stock will continue to be traded on Nasdaq on a split-adjusted basis beginning on August 22 under the company's existing trading symbol. The reverse stock split is intended to increase the bid price of the company's common stock so that Orion can regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on Nasdaq. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yahoo
an hour ago
- Yahoo
If I Could Only Buy and Hold a Single Stock, This Would Be It
Key Points Amazon and its management team are experienced with trying new things. Every success or failure, however, is a learning experience. History has shown that companies that foster innovation and don't punish failure tend to thrive, while those that fear it or are unwilling to adapt often struggle. 10 stocks we like better than Amazon › Investors can own as many individual stocks as they want and can afford. Sometimes, though, hypothetically imagining that you're limited to just one can be enlightening. That thought experiment forces you to rate and rank the strengths and flaws of every investment candidate on your radar. This process can -- in a good way -- really help you narrow down your list to a small handful of top options. Or one. And I know exactly which one that would be for me. If I could only buy and hold a single stock, it would be Amazon (NASDAQ: AMZN). Here's why. What Amazon really is You very likely already know the company. Amazon is, of course, the king of North American e-commerce, accounting for nearly 40% of the market's total revenue, according to research by Digital Commerce 360. It's doing alright overseas, too. Then there's its cloud computing arm, Amazon Web Services, which provides a relatively small portion of its revenue, but is responsible for nearly 60% of the company's operating profits. However, these numbers still don't even come close to telling the whole story. Amazon also manages an on-demand video platform (Prime), owns grocery store chain Whole Foods Markets, does delivery work for other online retailers, and sells prescription pharmaceuticals through its Pillpack arm. It also monetizes its online mall by allowing its sellers to pay for more prominent promotion, creating an advertising business that generated $15.7 billion in revenue last quarter alone, by the way. On top of all that, it owns websites and Twitch, and is the parent to camera-doorbell brand Ring. There's a method to the madness behind these seemingly disparate lines of business, though. While most companies focus on doing one or two things extremely well, Amazon has orchestrated several different lines of business, each of which fuels another, and each of which is fueled by another. The result is a mesh of different profit centers that ultimately funnels consumers and corporations into Amazon's ecosystem. Yes, it's complicated, but yes, Amazon can handle it. That's not quite the only reason I'd be willing to make Amazon my one and only stock holding, though. Jeff Bezos started it Companies founded or grown by bigger-than-life leaders can make for potentially problematic investments. It's just difficult to determine if it's the company that's something special, or the person. If it's the person, what happens when that individual is no longer at the helm? Case in point: General Electric was never quite the same after Jack Welch stepped down as CEO in 2001. Steve Jobs was also nearly synonymous with Apple until he passed the torch to Tim Cook in 2011. While Cook has been a solid successor, he's arguably not quite as captivating or magical as his predecessor. Neither is Apple under him. Still, most high-profile chief executives -- and founders in particular -- manage to leave their mark on their company's culture. That imprint remains part of the organization's ethos even in their absence. While current Amazon CEO Andy Jassy is no Jeff Bezos, for instance, Bezos' philosophy remains. Take, for example, the company's willingness to experiment. As Bezos noted in his 2016 letter to Amazon's shareholders, "Most large organizations embrace the idea of invention, but are not willing to suffer the string of failed experiments necessary to get there." That does not describe Amazon, though. Bezos made a point of fostering a "fail fast, fail often" work culture that did end up producing some failures, such as the Fire smartphone. Such experiments, however, also led to the creation of Amazon Web Services and Amazon Prime, the latter of which has been a massive growth driver for the company. Now Jassy is blending his own mindset with Bezos'. As he said while discussing the company's core 16 leadership principles, "At Amazon, you are not just empowered to speak up if you think we're doing something wrong for customers of the business. You're expected to do so, regardless of level." It works. Amazon is an even bigger company now than it was when Bezos stepped down as CEO. Don't underestimate the power of a willingness to innovate Many investors will point out that a healthy corporate culture doesn't pay the bills. I agree. At some point, to thrive, every company must sell its products or services profitably. Amazon is no exception. History has shown, however, that companies with corporate cultures that encourage innovation and don't punish failure tend to prosper while organizations that are cautiously and defensively managed often struggle. Compare Alphabet today to post-Welch GE, for instance. The manufacturing conglomerate ultimately hit a wall after years of obscuring the true depth of its insurance arm's liabilities from a management team that might have been able to fix them (although the company didn't exactly embrace the advent of the digital age either). Or compare Blockbuster to Netflix. The once-giant video rental chain infamously had a chance to buy the latter for a mere $50 million back in 2000. At the time, Blockbuster was doing on the order of $4 billion worth of business per year, and could have easily purchased Netflix, if only to take its budding competitor out of the market. But it didn't. In its defense, Blockbuster's decision at the time wasn't quite the obvious misstep it seems in retrospect. Remember, Netflix wasn't yet streaming then. It was still only renting DVDs by mail. Given Blockbuster's dominance of the brick-and-mortar movie rental business back in 2000, the logistics behind this new kind of movie rental business model understandably didn't make sense to the now-defunct company. In many regards, though, that story underscores the underlying theme here in an even more effective way. Even if Blockbuster didn't want Netflix, Blockbuster certainly could have leveraged its own powerful brand to become a streaming powerhouse. Likewise, if not Netflix, some other enterprising outfit would have eventually launched the streaming-video business. Netflix was simply the outfit that tried the idea out first, knowing when it did so that it might end in failure. So for my money, I'll bet on a company that is experienced with managing experiments' successes as well as failures -- and learning from both -- to evolve and thrive. That said, it certainly doesn't hurt the bullish argument that Amazon has the financial flexibility to experiment. With its $2.5 trillion market cap, it does more than $600 billion worth of business per year, and turns about $60 billion of that into net income. Meanwhile, it's only sitting on a little over $80 billion in long-term debt. It's much easier not to fear failure when you can actually afford to take big swings, miss, and try again. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 James Brumley has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, and Netflix. The Motley Fool recommends GE Aerospace. The Motley Fool has a disclosure policy. If I Could Only Buy and Hold a Single Stock, This Would Be It was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here?
GoodRx (GDRX) shares soared nearly 50% on Monday after announcing a GLP-1 partnership with the Danish pharmaceutical behemoth Novo Nordisk (NVO). In a press release this morning, the Nasdaq-listed firm said 'all strengths of Ozempic and Wegovy pens are now available to eligible self-paying patients for $499-per-month through GoodRx.' More News from Barchart Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Cathie Wood Is Buying BLSH Stock After the Bullish IPO. Should You? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! GoodRx stock has slightly outperformed in 2025, up just over 12% in the year to date. How Novo Deal May Help GoodRx Stock Teaming up with Novo Nordisk is a major win for GDRX shares because it positions the healthcare platform at the center of the booming GLP-1 weight-loss and diabetes drug market. Offering Ozempic and Wegovy at a flat $499 per month to self-paying customers helps GoodRx expand access to high-demand medications while reinforcing its value proposition as a cost-saving platform. Over time, this could drive user growth, boost engagement, and attract new pharmacy and pharma partnerships as well. In short, with GLP-1 drugs making headlines and consumer interest soaring, GoodRx stock is now tied to one of the most lucrative trends in healthcare. Why BofA Remains Bearish on GDRX Shares Despite the aforementioned positives, Bank of America analyst Allen Lutz says the Novo Nordisk deal is far from a sufficient reason to load up on GoodRx shares at current levels. In a note to clients, Lutz argued widespread pharmacy closures and changing reimbursement policy could make it difficult for GDRX stock to retain momentum in the days ahead. On Monday, the BofA analyst maintained his 'Underperform' rating and $3.40 price target on the healthcare platform, indicating potential downside of more than 30% from here. Wall Street Disagrees with BofA on GoodRx Investors should note, however, that Bank of America Securities is among the more bearish Wall Street firms on GoodRx stock in 2025. According to Barchart, the consensus rating on GDRX shares remains at 'Moderate Buy' with the mean target of $5.49 indicating potential 'upside' of another 5% from current levels. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
